Objective: To develop comprehensive recommendations for the treatment of the various
clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a …

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Objective: To develop an evidence-based guideline for the pharmacologic and
nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the …

Background Inflammatory cytokines such as tumor necrosis factor (TNF) have been
implicated in the pathogenesis of psoriasis. We evaluated the safety and efficacy of …

Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin
and joint manifestations affecting approximately 2% of the population. In this first of 5 …

Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin
and joint manifestations affecting approximately 2% of the population. In this fourth of 6 …

Psoriasis is a common papulosquamous skin disease. The histopathology is characterized
by epidermal hyperplasia and inflammation. Recent studies suggest that keratinocyte …

Background Psoriasis has substantial psychological and emotional effects. We assessed the
effect of etanercept, an effective treatment for the clinical symptoms of psoriasis, on fatigue …

Background Interleukin 17A is a proinflammatory cytokine that is implicated in the
pathogenesis of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous …

Objective To update the 2009 Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations …